参考文献/References:
[1] 王宙, 周琳, 刘洋, 等. 慢性心力衰竭的流行病学研究现状及其防治研究进展[J]. 中国循证心血管医学杂志,2019,11(8):1022-1024.WANG Zhou, ZHOU Lin, LIU Yang, et al. Currentsituation of epidemiology and prevention of chronicheart failure [J]. Chinese Journal of Evidence-BasesCardiovascular Medicine, 2019,11 (8): 1022-1024.
[2] G??ER H, KAYACIK G?NDAY ?, ?NAL M.The risk of arrhythmia by calculating with newelectrocardiographic parameters in pregnant womenwith heart failure[J]. Turkish Journal of Clinics andLaboratory, 2018, 9(4): 331-335.
[3] 刘冰, 张卫海, 傅强, 等.Cys C,NT-proBNP,cTnT在急性心力衰竭患者中的水平及其联合检测的诊断价值[J]. 心血管康复医学杂志,2018,27(3):282-286.LIU Bin, ZHANG Weihai, FU Qiang, et al. Levelsof Cys C ,NT-proBNP and cTnT in AHF patientsand diagnostic value of their combined detection[J].Chinese Journal of Cardiovascular RehabilitationMedicine, 2018, 27 (3): 282-286.
[4] 赵廷利, 孙启梅, 王辉. 心力衰竭患者血清sST2 及ANG-2 与Cys C 联合检测诊断效能研究[J]. 社区医学研究, 2019, 17(20): 1299-1302.ZHAO Tingli,SUN Qimei,WANG Hui. Study onthe diagnostic efficacy of serum sST2,Ang-2 and CysC in patients with heart failure[J]. J Community Med ,2019, 17(20): 1299-1302.
[5] 吴献豪, 刘宝宏.BNP 和Cys-C 检测在致心律失常右室发育不良患者心衰预测及预后评估中的价值[J]. 中国循证心血管医学杂志, 2018, 10 (5): 597-600.WU Xianhao, LIU Baohong. Value of brain natriureticpeptide and serum cystatin C in predicting heart failureand prognosis review in patients with arrhythmogenicright ventricular dysplasia [J]. Chinese Journal ofEvidence-Based Cardiovascular Medicine, 2018, 10(5): 597-600.
[6] 尚少红, 张红, 李湘. 血清Cystatin C,MMP-2 及hs-CRP/PAB 对急性心肌梗死患者PCI 术后并发心衰的预测价值[J]. 河北医药,2019,41(3):343-346,351.SHANG Shaohong, ZHANG Hong, LI Xiang. Predictivevalue of serum Cystatin C, MMP2 combined withhs-CRP/PAB ratio in patients with acute myocardial infartioncomplicated by heart failure after PCI[J]. HebeiMedical Journal,2019,41(3):343-346,351.
[7] HUNT S. 2009 update incorporated into the ACC/AHA2005 guidelines for the diagnosis and managementof heart failure in adults[J]. Journal of the AmericanCollege of Cardiology, 2009, 53(2): 164-170.
[8] 郭飞波.Cyp A, BNP, ET-1 浓度在老年慢性心衰患者中的表达及临床意义[J]. 现代检验医学杂志, 2016,31 (6): 88-91.GUO Feibo. Expression characteristics and clinicalsignificance of CypA,BNP and ET-1 in elderly patientswith chronic heart failure[J]. Journal of ModernLaboratory Medicine, 2016, 31 (6): 88-91.
[9] 马炜. 胺碘酮联合厄贝沙坦治疗心力衰竭合并心律失常的疗效及对心功能的影响[J]. 实用临床医药杂志,2018,22(13):42-44, 48.MA Wei. Effect of amiodarone combined with irbesartanon treatment of patients with heart failure andarrhythmia and its influence on cardiac function [J].Journal of Clinical Medicine in Practice, 2018, 22 (13):42-44, 48.
[10] 陈菲菲, 赵谊昶, 尹晓盟, 等. 慢性心力衰竭患者心脏再同步化治疗后心律失常导管消融现状[J]. 中华心血管病杂志, 2019, 47 (11): 927-930.CHEN Feifei, ZHAO Yichang,YIN Xiaomeng, etal. Current status of catheter ablation for arrhythmiaafter cardiac resynchronization therapy in patients withchronic heart failure [J]. Chinese Journal of Cardiology,2019, 47 (11): 927-930.
[11] BAZOUKIS G, LETSAS K P, TSE G, et al. Predictorsof arrhythmia recurrence in patients with heart failureundergoing left atrial ablation for atrial fibrillation[J].Clinical Cardiology, 2018, 41(1): 63-67.
[12] 李腾, 李宜富. 心房颤动合并心力衰竭患者: 导管消融获益的认识[J]. 内科急危重症杂志, 2018, 24 (6):447-448.LI Teng, LI Yifu. Patients with atrial fibrillation andheart failure: understanding the benefits of catheterablation [J]. Journal of Internal Intensive Medicine,2018, 24 (6): 447-448.
[13] 陈泽芳, 赖志杰, 辛延国, 等. 射血分数保留型心力衰竭合并心房颤动的发病机制及治疗进展[J]. 临床内科杂志, 2019 ,36(2): 142-144.CHEN Zefang, LAI Zhijie, XIN Yanguo, et al. Pathogenesisand treatment progress of heart failure withpreserved ejection fraction and atrial fibrillation [J].Journal of Clinical Internal Medicine, 2019 ,36(2): 142-144.
[14] OKABE T. Cardiac arrhythmia in heart failure[J].Encyclopedia of Cardiovascular Research andMedicine, 2018, 7(15): 394-410.
[15] 聂蔚卓, 丁超, 蔡青青, 等. 重组人脑利钠肽对慢性心力衰竭患者QTcd 及短期预后的影响[J]. 临床误诊误治, 2018, 31 (1): 97-100.NIE Weizhuo, DING Chao, CAI Qingqing, et al. Effectof recombinant human brain natriuretic peptide onQTcd and short-term prognosis of patients with chronicheart failure [J]. Clinical Misdiagnosis & Mistherapy,2018, 31 (1): 97-100.
[16] 周杰, 张智. 胺碘酮综合治疗重度心力衰竭并发快速心律失常疗效观察[J]. 医学临床研究, 2019,36(6):1216-1218.ZHOU Jie, ZHANG Zhi. Effect of amiodarone onsevere heart failure complicated with tachyarrhythmia[J]. Journal of Clinical Research, 2019,36 (6):1216-1218.
[17] DIMITROPOULOS G, LEVENTOGIANNIS G, DEBONO J. Decompensated heart failure with ventriculararrhythmia: how useful is VT ablation[J]. Current HeartFailure Reports, 2018, 15(4): 201-213.
[18] 刘玉, 周利民, 张军. 心率变异性对慢性心力衰竭病情评估及预后的应用价值[J]. 新疆医科大学学报,2018,41 (3): 291-294.LIU Yu, ZHOU Limin, ZHANG Jun. Application ofheart rate variability in assessment and prognosis ofchronic heart failure [J]. Journal of Xinjiang MedicalUniversity, 2018,41 (3): 291-294.
[19] 黄德嘉, 张澍. 慢性心力衰竭最佳药物治疗与心脏性猝死的预防[J].中华心律失常学杂志, 2018, 22 (1):4-7.HUANG Dejia, ZHANG Shu. Optimal medicaltherapy of chronic heart failure and prevention ofsudden cardiac death [J]. Chinese Journal of CardiacArrhythmias, 2018, 22 (1): 4-7.
[20] 浩日瓦, 娜日罕, 周红, 等. 血清microRNA126 和microRNA1 检测对心衰诊断价值的研究[J]. 现代检验医学杂志,2018,33(3):18-20, 23.HAO Riwa,NA Rihan,ZHOU Hong, et al. Study onthe diagnostic value of detecting serum microRNA126and microRNA1 in heart failure [J]. Journal of ModernLaboratory Medicine, 2018, 33 (3): 18-20,23.
[21] CHRISTIE S, HIEBERT B, SEIFER C M, et al.Clinical outcomes of cardiac resynchronization therapywith and without a defibrillator in elderly patients withheart failure[J]. Journal of Arrhythmia, 2019, 35(1): 61-69.
[22] 杨宏斌, 黄巧平. 老年心功能衰竭患者血清NTproBNP和hs-TnT 水平检测与NYHA 分级的相关性分析[J].现代检验医学杂志, 2019, 34 (2): 64-67,71.YANG Hongbin, HUANG Qiaoping. Application ofcombined detection of serum NT-proBNP and hs-TnT by electrochemiluminescence in evaluation ofelderly patients with heart failure [J].Journal of ModernLaboratory Medicine, 2019, 34 (2): 64-67, 71.